Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sarah Church is active.

Publication


Featured researches published by Sarah Church.


Journal of Substance Abuse Treatment | 2002

Behavioral naltrexone therapy: An integrated treatment for opiate dependence

Jami L. Rothenberg; Maria A. Sullivan; Sarah Church; Angela M. Seracini; Eric D. Collins; Herbert D. Kleber; Edward V. Nunes

Treatment of opiate dependence with naltrexone has been limited by poor compliance. Behavioral Naltrexone Therapy (BNT) was developed to promote adherence to naltrexone and lifestyle changes supportive of abstinence, by incorporating components from empirically validated treatments, including Network Therapy with a significant other to monitor medication compliance, the Community Reinforcement Approach, and voucher incentives. An overview is presented of the BNT treatment manual. In an uncontrolled Stage I trial (N = 47), 19% completed the 6-month course of treatment. Retention was especially poor in the subsample of patients who were using methadone at baseline (N = 18; 39% completed 1 month, none completed 6 months), and more encouraging among heroin-dependent patients (N = 29; 65% completed 1 month, 31% completed 6 months). Thus, attrition continues to be a serious problem for naltrexone maintenance, although further efforts to develop interventions such as BNT are warranted.


Neurotoxicology and Teratology | 1992

Prenatal administration of methadone using the osmotic minipump: Effects on maternal and offspring toxicity, growth, and behavior in the rat

Donald E. Hutchings; Ann C. Zmitrovich; Stephen C. Brake; Daniel Malowany; Sarah Church; Thomas J. Nero

Two doses of methadone were administered by osmotic minipump from day 8 of gestation through parturition. A pair-fed control group received saline via minipump and was allowed to eat and drink only the amount consumed by the high dose group on the same gestation days. A nontreated control group was left undisturbed during pregnancy. All treated and control litters were fostered at birth to untreated dams. Naloxone challenge of the dams after parturition showed that drug treatment produced physical dependence. Methadone treatment reduced maternal weight gain but had no effect on either the frequency of resorptions or birthweight. Both doses of methadone increased perinatal mortality but only the high dose produced a decrement in postnatal growth. To examine the effects of methadone on the rest-activity cycle of the offspring, groups of three littermates from each of the treated and control groups were tested for an 8 h observation period on electronic activity monitors at 22 days of age. No behavioral effects were observed for either control group or the low dose methadone group. The high dose methadone offspring, however, spent less time resting, showed disrupted rhythmicity, and poor state regulation. These findings are discussed in relation to earlier studies using once per day methadone administration as well as clinical descriptions of infants undergoing opiate abstinence.


American Journal of Drug and Alcohol Abuse | 2001

Concurrent substance use and outcome in combined behavioral and naltrexone therapy for opiate dependence.

Sarah Church; Jami L. Rothenberg; Maria A. Sullivan; Greg Bornstein; Edward V. Nunes

The effect of concurrent nonopiate drug use on outcome of treatment for opiate dependence. Method: Forty-seven opiate-dependent patients received a 6-month course of outpatient treatment with naltrexone and cognitive-behavioral therapy (behavioral naltrexone therapy, BNT) at a university-based research clinic. Opiate-negative urines and naltrexone ingestion were rewarded with monetary vouchers. Abstinence from other drugs was encouraged verbally, but no contingencies were placed on nonopiate drug use. The proportions of all urines (collected twice weekly) positive for cocaine, cannabis, and benzodiazepines over the course of treatment were evaluated as predictors of outcome of opiate dependence treatment, as measured by proportion of opiate-positive urines, days retained in treatment, and proportion of naltrexone doses taken, using Pearson product moment correlations and oneway analysis of variance (ANOVA). Results: The majority of patients (78%) used a nonopiate drug at least once during the trial. There were no significant correlations between concurrent drug use measures and opiate dependence treatment outcomes, indicating no simple linear relationship between these measures. However, when concurrent drug use was trichotomized into abstinent, intermittent, and heavy use groups, groups with intermittent use had superior outcome compared to both abstinent and heavy use groups in several contrasts. Conclusions: Intermittent use of nonopiate drugs is common during outpatient treatment for opiate dependence and may be a favorable prognostic indicator. This may support a “harm reduction” approach as opposed to a strict abstinence-oriented approach. Further research is needed to identify the optimal therapeutic stance toward other drug use during treatment for opiate dependence.


Neurotoxicology and Teratology | 1993

Prenatal administration of methadone in the rat increases offspring acoustic startle amplitude at age 3 weeks

Donald E. Hutchings; Ann C. Zmitrovich; Stephen C. Brake; Sarah Church; Daniel Malowany

Two doses of methadone were administered by osmotic minipump from Day 8 of gestation through parturition, a dosing technique previously shown to produce physical dependence in the dams. A pair-fed control group received saline via minipump and was allowed to eat and drink only the amount consumed by the high dose group on the same gestation days. A nontreated control group was left undisturbed during pregnancy. All treated and control litters were fostered at birth to untreated dams. The effects of methadone on maternal and offspring toxicity replicated our previous findings. At 21-23 days of age, acoustic startle amplitude was measured for each treated and control animal. Because prenatal methadone exposure resulted in reduced body weight at the time of testing, it was necessary to analyze startle amplitude using weight as a covariate. This analysis showed that the methadone treated offspring had a significantly enhanced mean startle amplitude compared with the controls. These findings support the hypothesis derived from our earlier research that prenatal exposure to methadone produces a prolonged state of CNS hyperexcitability similar to clinical descriptions of human infants undergoing opiate abstinence.


Pharmacology, Biochemistry and Behavior | 1992

Effects of prenatal exposure to cocaine on the rest-activity cycle of the preweanling rat

Ann C. Zmitrovich; Donald E. Hutchings; Diana Dow-Edwards; Daniel Malowany; Sarah Church

Either 45 or 60 mg/kg cocaine HCl was administered from days 8-22 of gestation. Pair-fed and nontreated groups served as controls and all treated and control litters were fostered at birth to untreated dams. To examine whether cocaine produces effects on the rest-activity cycle of the offspring, groups of three littermates from each of the treated and control groups were tested for an 8-h observation period on electronic activity monitors at 22 days of age. Neither activity level nor the rest-activity pattern were affected by cocaine. These findings are discussed in relation to previous studies of cannabis and methadone effects on the rest-activity measure.


Addictive Behaviors | 2006

Drug Stroop performance : Relationships with primary substance of use and treatment outcome in a drug-dependent outpatient sample

Kenneth M. Carpenter; Elizabeth A. Schreiber; Sarah Church; David McDowell


Addiction | 2016

Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study

Walter Ling; Maureen Hillhouse; Andrew J. Saxon; Larissa Mooney; Christie Thomas; Alfonso Ang; Abigail G. Matthews; Albert Hasson; Jeffrey J. Annon; Steve Sparenborg; David Liu; Jennifer McCormack; Sarah Church; William Swafford; Karen Drexler; Carolyn Schuman; Stephen Ross; Katharina Wiest; P. Todd Korthuis; William B. Lawson; Gregory S. Brigham; Patricia C. Knox; Michael A. Dawes; John Rotrosen


Annali dell'Istituto Superiore di Sanità | 1993

Methadone during pregnancy: the search for a valid animal model.

Donald E. Hutchings; Ann C. Zmitrovich; Sarah Church; Daniel Malowany


Psyccritiques | 2004

Lessons Learned From Project MATCH.

Sarah Church


Addiction | 2016

Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study: Buprenorphine for cocaine use disorders

Walter Ling; Maureen Hillhouse; Andrew J. Saxon; Larissa Mooney; Christie Thomas; Alfonso Ang; Abigail G. Matthews; Albert Hasson; Jeffrey J. Annon; Steve Sparenborg; David Liu; Jennifer McCormack; Sarah Church; William Swafford; Karen Drexler; Carolyn Schuman; Stephen Ross; Katharina Wiest; P. Todd Korthuis; William B. Lawson; Gregory S. Brigham; Patricia C. Knox; Michael A. Dawes; John Rotrosen

Collaboration


Dive into the Sarah Church's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Albert Hasson

University of California

View shared research outputs
Top Co-Authors

Avatar

Alfonso Ang

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David Liu

National Institute on Drug Abuse

View shared research outputs
Top Co-Authors

Avatar

Gregory S. Brigham

University of Cincinnati Academic Health Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge